Amendments to the Claims:

1. (Currently Amended) A sustained release oral matrix tablet comprising a single function layer, wherein the single functional layer comprises alfuzosin or pharmaceutically acceptable salt, solvate, enantiomers or mixtures thereof, and a release-retarding agent comprising ~~in~~ a combination of hydroxypropylmethyl cellulose and hydroxypropyl cellulose.

2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Currently Amended) The sustained release tablet of claim 1, wherein the ~~tablet~~ single function layer further comprises one or more pharmaceutically acceptable excipients.

6. (Previously presented) The sustained release tablet of claim 5, wherein the one or more pharmaceutically acceptable excipients comprise one or more of binders, diluents, and lubricants/glidants.

7. (Previously presented) The sustained release tablet of claim 6, wherein the binders comprise one or more of polyvinyl pyrrolidone, pregelatinized starch, and gelatin.

8. (Previously presented) The sustained release tablet of claim 6, wherein the diluents comprise one or more of lactose, mannitol, and microcrystalline cellulose.

9. (Previously presented) The sustained release tablet of claim 6, wherein the lubricants comprise one or more of magnesium stearate, zinc stearate, talc, and colloidal silicon dioxide.

10. (Currently Amended) The sustained release tablet of claim 1, wherein the ~~tablet~~ single function layer comprises between about 10% to about 90% w/w of hydroxypropyl methylcellulose and between about 10% to about 90% w/w of hydroxypropyl cellulose.

11. (Cancelled)

12. (Cancelled)

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)

16. (Cancelled)

17. (Cancelled)

18. (Previously presented) The sustained release tablet of claim 1, further comprising one or more nonfunctional layers surrounding the tablet.

19. (Cancelled)

20. (Cancelled)

21. (Cancelled)

22. (Cancelled)

23. (Cancelled)

24. (Cancelled)

25. (Cancelled)

26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

29. (Currently Amended) A process for forming a sustained release oral matrix tablet comprising a single functional layer, the process comprising:

forming a mixture of alfuzosin or pharmaceutically acceptable salt, solvate, enantiomers or mixtures thereof and a release-retarding agent comprising

compressing the mixture into a tablet; and

optionally coating the tablet with one or more nonfunctional layers.

30. (Cancelled)

31. (Cancelled)

32. (Cancelled)

33. (Cancelled)

34. (Cancelled)

35. (Previously presented) The process of claim 29, wherein the mixture is granulated by wet granulation or dry granulation.

36. (Cancelled)

37. (Previously presented) The process of claim 29, wherein forming a mixture further comprises one or more pharmaceutically acceptable excipients.

38. (Cancelled)

39. (Cancelled)

40. (Cancelled)